DOI QR코드

DOI QR Code

건강한 자원자에서 JES9501 단회 및 반복 경구투여 후 안전성 및 약동.약력학적 특성에 관한 연구

Pharmacokinetics, Pharmacodynamics and Safety of JES9501 after Single and Multiple Oral Administration in Healthy Subjects

  • 김언혜 (서울대학교 의과대학 임상약리학교실 및 서울대학교병원 임상약리학과) ;
  • 김보형 (경희대학교병원 임상약리학과) ;
  • 신동성 (서울대학교 의과대학 임상약리학교실 및 서울대학교병원 임상약리학과) ;
  • 조주연 (서울대학교 의과대학 임상약리학교실 및 서울대학교병원 임상약리학과) ;
  • 유경상 (서울대학교 의과대학 임상약리학교실 및 서울대학교병원 임상약리학과) ;
  • 장인진 (서울대학교 의과대학 임상약리학교실 및 서울대학교병원 임상약리학과) ;
  • 정재용 (서울대학교 의과대학 임상약리학교실 및 분당서울대학교병원 임상시험센터)
  • Kim, AnHye (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Kim, Bo-Hyung (Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital) ;
  • Shin, Dongseong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Cho, Joo-Youn (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Chung, Jae-Yong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital)
  • 투고 : 2013.11.13
  • 심사 : 2013.12.28
  • 발행 : 2013.12.31

초록

Background: JES9501 is dehydroevodiamine, the extract of Evodia rutaecarpa, expected to be a new therapeutic for Alzheimer disease. This study aims to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of JES9501 after single or multiple dosing. Methods: A double-blind, randomized, placebo-controlled, dose ascending, parallel study was conducted in healthy subjects. A single dose of JES9501 50 100 200 400 or 800 mg and multiple doses of JES9501 100 200 or 400 mg once-daily for 7days was administered. Serial blood and urine samples for PK evaluation were collected. Acetylcholinesterase (AChE) activity was measured for PD evaluation in multiple dose group. Results: In the single dose study, means of dose-normalized peak concentration ($C_{max}$) of 100 200 400 and 800 mg dose group are comparable except 50 mg dose group. Means of dose-normalized area under the plasma concentration-time curve (AUC) from dosing to the last quantifiable concentration of corresponding dose group were similar. At steady state in the multiple dose study, means of dose-normalized $C_{max}$ and AUC for dosing interval of 100 200 and 400 mg dose group decreased as the dose increased, however those were not relevant. There was no significant difference of AChE activity between three dosage groups and placebo group. Adverse events related to study drug were all mild and there were no remarkable findings. Conclusion: JES9501 was safe and well-tolerated after single or multiple doses in healthy male subjects. Further studies are warranted to evaluate the PK of optimized dosage form and to prove the drug effect in clinical trials for Alzheimer disease patients.

키워드

참고문헌

  1. Seoul National University Hospital. Nationwide Study on the Prevalence of Dementia in Korean Elders. 2008. (Korean)
  2. Han SH. Novel Pharmacotherapies for Alzheimer's Disease. J Korean Med Assoc, 2009;52(11):1059-1068. (Korean) https://doi.org/10.5124/jkma.2009.52.11.1059
  3. Williams P, Sorribas A, Howes M J. Natural products as a source of Alzheimer's drug leads. Nat Prod Rep, 2011;28(1):48-77. https://doi.org/10.1039/c0np00027b
  4. Lee JY, Cha MR, Chois CW, Kim YS, Lee BH, Ryu SY. Cholinesterase Inhibitors Isolated from the Fruits Extract of Evodia officinalis. Kor J Pharmacogn, 2012;43(2):122-126. (Korean)
  5. Lee SW, Hwang, BY, Kim, SE, Kim HM, Kim YH, Lee KS, Lee JJ, Ro JS. Isolation of modulators for multdrug resistance from the fruits of Evodia officinalis. Kor J Pharmacogn, 1995;26(4):344-348. (Korean)
  6. Yun HJ, Heo SK, Lee YT, Park WH, Park SD. Anti-inflammatory effect of Evodia officinalis Dode in mouse macrophage and human vascular endotherial cells. Kor J Herbology, 2008;23(1):29-38. (Korean)
  7. ORHAN İ, SENER B. Acetylcholinesterase Inhibitors from Natural Resources. FABAD J Pharm Sci, 2003;28:51-58.
  8. Jeil Pharmaceutical Co., Ltd. Investigator's Brochure. 2003. (Korean)
  9. FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Guidance for Industry. 2005.
  10. Mosca A, Ghezzi A, Luzzana M, Paleari R, Imbimbo BP, Pharmacodynamic monitoring of eptastigmine in capillary blood. Eur J Clin Pharmacol, 1996;50(5):425-427. https://doi.org/10.1007/s002280050135
  11. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta, 1999;288(1-2):73-90. https://doi.org/10.1016/S0009-8981(99)00144-8
  12. Lotti M. Cholinesterase inhibition: complexities in interpretation. Clin Chem, 1995;41(12): 1814-1818.
  13. Augustinsson K-B. The normal variation of human blood cholinesterase activity. Acta Physiol Scand, 1955;35(1):40-52. https://doi.org/10.1111/j.1748-1716.1955.tb01262.x
  14. Sidell FR, Kaminskis A. Influence of age, sex, and oral contraceptives on human blood cholinesterase activity. Clin Chem, 1975;21(10): 1393-1395.
  15. Biagioni MC, Galvin JE. Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag, 2011;1(2):127-139. https://doi.org/10.2217/nmt.11.11
  16. Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B. Biomarkers in Alzheimer's disease: not yet surrogate endpoints. Ann N Y Acad Sci, 2009;1180: 119-124. https://doi.org/10.1111/j.1749-6632.2009.04947.x
  17. Galasko D, Golde TE. Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems. Alzheimers Res Ther, 2013;5(2):10. https://doi.org/10.1186/alzrt164